Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 17, 2016 - Issue 10
Submit an article Journal homepage
442
Views
15
CrossRef citations to date
0
Altmetric
Original Research

The efficacy and safety of teneligliptin added to ongoing metformin monotherapy in patients with type 2 diabetes: a randomized study with open label extension

Andrew BrysonClinical Department, Mitsubishi Tanabe Pharma Europe Ltd, London, UKCorrespondence[email protected]
,
Paul E JenningsCenter for Diabetes and Endocrinology, York Teaching Hospital NHS Foundation Trust Ringgold, York, UK
,
Laszlo DeakDepartment of Internal Medicine, Kaposi Mor County Hospital, Kaposvar, Hungary
,
Fraga S PaveliuDepartment of Nutrition and Endocrinology, Societatea Civila Medicala, Bucharest, Romania
&
Matt LawsonClinical Department, Mitsubishi Tanabe Pharma Europe Ltd, London, UK
Pages 1309-1316 | Received 11 Mar 2016, Accepted 12 May 2016, Published online: 26 May 2016

References

  • Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia. 2003;46:3–19.
  • Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 2005;365:1333–1346.
  • Avignon A, Radauceanu A, Monnier L. Non-fasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care. 1997;20:1822–1826.
  • Shichiri M, Kishikawa H, Ohkubo Y, et al. Long-term results of the Kumamoto study on optimal diabetes control in type 2 diabetic subjects. Diabetes Care. 2000;23:B21–B29.
  • Guideline for management of post meal glucose in diabetes. International diabetes federation; 2011. Available from: http://www.idf.org/2011-guideline-management-postmeal-glucose-diabetes.
  • Frontoni S, Di Bartolo P, Avogaro A, et al. Glucose variability: an emerging target for the treatment of diabetes mellitus. Diabetes Res Clin Pract. 2013;102(2):86–95.
  • Wang XC, Liu H, Chen J, et al. Multiple factors related to the secretion of Glucagon-Like Peptide-1. Int J of Endocrinol. 2015;11. Article ID 651757. doi:10.1155/2015/651757.
  • Scheen AJ. Current management of coexisting obesity and type 2 diabetes. Drugs. 2003;63:1165–1184.
  • Scheen AJ. Drug interactions of clinical importance with antihyperglycaemic agents: an update. Drug Safety. 2005;28:601–631.
  • Scheen AJ. Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin Pharmacokinet. 2007;46:93–108.
  • Goda M, Kadowaki T. Teneligliptin for the treatment of type 2 diabetes. Drugs Today (Barc). 2013;49(10):615–629.
  • Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obesity Metab. 2010;12:648–658.
  • Nakamaru Y, Hayashi Y, Ikegawa R, et al. Metabolism and disposition of the dipeptidyl peptidase IV inhibitor teneligliptin in humans. Xenobiotica. 2013. doi:10.3109/00498254.2013.816891.
  • Halabi A, Maatouk H, Siegler KE, et al. Pharmacokinetics of teneligliptin in subjects with renal impairment. Clin Pharmacol Drug Dev. 2013;2(3):246–254.
  • Eto T, Inoue S, Kadowaki T. Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial. Diabetes Obes. 2012;14:1040–1046.
  • Kadowaki T, Marubayashi F, Yokota S, et al. Safety and efficacy of teneligliptin in Japanese patients with type 2 diabetes mellitus: a pooled analysis of two phase III clinical studies. Expert Opin Pharmacother. 2015;16(7):971–981.
  • NICE. Type 2 diabetes. Guidance. 2008;CG87:13.
  • EMEA: note for guidance on clinical investigation of medicinal products in the treatment of diabetes mellitus (CPMP/EWP/1080/00) 2002 May.
  • Scheen AJ. Metformin + saxagliptin for type 2 diabetes. Expert Opin Pharmacother. 2012;13(1):139–146.
  • American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2015;38(Suppl 1):S35.
  • Kadowaki T, Kondo K. Efficacy, safety and dose response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2013;15:810–818.
  • Kim MK, Rhee EJ, Han KA, et al. Efficacy and safety of teneligliptin, a dipeptidyl peptidase-4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled phase III trial. Diabetes Obes Metab. 2015;17:309–312.
  • Strain WD, Lukashevich V, Hoellinger MJ, et al. Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study. Lancet. 2013;382:409–416.
  • Fonseca V, Staels B, Morgan JD, et al. Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes. J Diabetes Complications. 2013;27(2):177–183.
  • Charbonnel B, Karasik A, Liu J, et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Care. 2006;29:2638–2643.
  • DeFronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care. 2009;32:1649–1655.
  • Bosi E, Dotta F, Jia Y, et al. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2009;11(5):506–515.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.